title: Outcomes of Lung Transplantation in Recipients With Hepatitis C Virus Infection.
abstract: Hepatitis C virus (HCV) infection negatively impacts patient and graft survival following nonhepatic solid organ transplantation. Most data, however, are in kidney transplant, where despite modest impact on outcomes, transplantation is recommended for those with mild to moderate hepatic fibrosis given overall benefit compared to remaining on dialysis. In lung transplantation (LuTx), there is little data on outcomes and international guidelines are vague on the criteria under which transplant should be considered. The University of Alberta Lung Transplant Program routinely considers patients with HCV for lung transplant based on criteria extrapolated from the kidney transplant literature. Here we describe the outcomes of 27 HCV-positive, compared to 443 HCV-negative LuTx recipients. Prior to transplant, five patients were treated for HCV and cured. At the time of transplant, 14 patients remained HCV RNA positive. The 1-, 3-, and 5-year survival were similar in HCV RNA-positive versus -negative recipients at 93%, 77%, and 77% versus 86%, 75%, and 66% (p = 0.93), respectively. Long-term follow-up in eight patients demonstrated no significant progression of fibrosis. In our cohort, HCV did not impact LuTx outcomes and in the era of interferon-free HCV therapies this should not be a barrier to LuTx.
authors.affiliation: Division of Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: K E
authors.initials: KE
authors.lastname: Doucette
authors.affiliation: Division of Pulmonary Medicine, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: K
authors.initials: K
authors.lastname: Halloran
authors.affiliation: Division of Pulmonary Medicine, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Kapasi
authors.affiliation: Division of Pulmonary Medicine, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: D
authors.initials: D
authors.lastname: Lien
authors.affiliation: Division of Pulmonary Medicine, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: J G
authors.initials: JG
authors.lastname: Weinkauf
mesh_terms: D000328:Adult; D005260:Female; D005355:Fibrosis / Q000209:etiology / Q000401:mortality*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000209:etiology / Q000401:mortality*; D006085:Graft Survival; D016174:Hepacivirus / Q000302:isolation & purification; D006526:Hepatitis C / Q000601:surgery* / Q000821:virology; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology / Q000401:mortality*; D016040:Lung Transplantation / Q000009:adverse effects / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology / Q000401:mortality*; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors
keywords: clinical research/practice; fibrosis; infection and infectious agents; infectious disease; lung transplantation/pulmonology; patient survival; viral: hepatitis C